CAS: 68327-11-7; (1R,2R)-2-Aminocyclopentanol Hydrochloride

该化合物是一种有机环球开蓬醇衍生物,在2位置上有一个立体的氨基氨基组,其硬环球开蓬丹基骨干和定义(1R,2R)配置使其成为非对称合成中有价值的中间体,特别是需要精确立体化学的药品和精细化学品.盐能增强稳定性和溶性,便于处理和储存.该化合物通常用于制备手链,催化剂和生物活性分子,其结构僵硬性和对等纯度在合成应用中促成高度选择性.其精密的立体化学化学学也支持药化学研究和抗生化选择性转化.

英文名称(1R,2R)-2-Aminocyclopentanol Hydrochloride
中文名称(1R,2R)-2-氨基环戊醇盐酸盐
IUPAC名称(1R,2R)-2-aminocyclopentan-1-ol hydrochloride
其它别名(1R,2R)-2-氨基-1-羟基环戊烷盐酸盐; Trans-2-Aminocyclopentanol Hydrochloride
CAS编号68327-11-7
MFCD编号:MFCD09834692
EINECS号:802-195-5
分子式:C5H12ClNO
分子量:137.61
产品CID: 1673220
产品分类有机原料→分子砌块→脂肪环类化合物→环戊烷类化合物

相似结构搜索
产品信息参考;;;;
InChIKey: ZFSXKSSWYSZPGQ-TYSVMGFPSA-N
InChI=1/C5H11NO.ClH/c6-4-2-1-3-5(4)7;/h4-5,7H,1-3,6H2;1H/t4-,5-;/s3…
计算化学: 氢键受体数2.0氢键供体数2可旋转键数0

相似化合物

59260-76-3 225791-13-9 31889-37-9

MSDS等安全信息

GHS象形图
GHS符号GHS07;
注释: Exclamation mark
危险类别皮肤腐蚀/刺激类别2
严重眼刺激类别2
特定目标器官毒性 - 单次接触类别3
严重眼刺激类别2A
警示词Warning(警告)
危险描述H315 |造成皮肤刺激.
H319 |造成严重眼刺激.
H335 |可能引起呼吸道刺激.
防范说明P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
UN编号NONH for all modes of transport
安全声明H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
WGK Germany3

欧盟法规

C&L通报

上下游产品

CAS号672310-36-0 (R,R)-2-N-benzy... | CAS号930-45-0 (1S,2S)-2-AMINO... | CAS号285-67-6 氧化环戊烯

合成工艺路线路线简述

合成目标产物 Trans-2-Aminocyclopentanol Hydrochloride 主要起始原料 Carbamic Acid, N-[(1R,2R)-2-Hydroxycyclopentyl]-, Phenylmethyl Ester
(文献来源)合成步骤主要原料 Carbamic Acid, N-[(1R,2R)-2-Hydroxycyclopentyl]-, Phenylmethyl Ester

1,2-环氧环戊烷置于ammonium Hydroxide,盐酸体系中,用水作为反应溶剂,化学反应 3.0H,以1600 Mg的收率获得产物(1R,2R)-反式-2-氨基环戊醇盐酸盐
参考文献: Cdk Inhibitor[fr] Inhibiteur De Cdk[zh] Cdk抑制剂
标题: Cdk Inhibitor[fr] Inhibiteur De Cdk[zh] Cdk抑制剂
摘要:一类作为选择性cdk抑制剂的化合物,含有所述化合物的药物组合物,制备所述化合物的有用中间体以及利用化合物制备治疗细胞增殖性疾病,例如癌症的药物,该化合物具有如式(I-A)所示的结构.

海关参考信息

2905122000-异丙醇
2922110001-单乙醇胺
2905142000-仲丁醇
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-9751877-B2
优先权日:2012-09-21
标题 :Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
发明人：PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; PATEL NANDINI CHATURBHAI; STIFF CORY MICHAEL; TRAN TUAN PHONG; KAUFFMAN GREGORY WAYNE; STEPAN ANTONIA FRIEDERIKE; VERHOEST PATRICK ROBERT
权利人:PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-7786301-B2
优先权日:2002-05-31
标题:Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof
发明人：DAHANUKAR VILAS A; NGUYEN HOA N; ORR CECILIA A; ZHANG FUCHENG; ZAVIALOV ILIA
权利人:SCHERING CORP
摘要:A process for preparing xanthine phosphodiesterase V inhibitors, and compounds utilized in said process. The process includes a five-step methodology for efficient synthesis of Compound 5 without intermediate purifications or separations, a dihalogenation step to synthesize Compound 7, and a coupling reaction to produce Compound 9.

专利号:EP-1719772-A1
优先权日:2002-05-31
标题:Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
发明人：DAHANUKAR VILAS H; NGUYEN HOA N; ORR CECILIA A; ZHANG FUCHENG; ZAVIALOV ILIA A
权利人:SCHERING CORP
摘要:A process for preparing xanthine phosphodiesterase V inhibitors, and compounds utilized in said process. The process includes a five-step methodology for efficient synthesis of Compound 5 without intermediate purifications or separations, a dihalogenation step to synthesize Compound 7, and a coupling reaction to produce Compound 9.